Pliant Therapeutics Files 8-K for Corporate Updates

Ticker: PLRX · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1746473

Pliant Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyPliant Therapeutics, Inc. (PLRX)
Form Type8-K
Filed DateJun 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, filing-update

Related Tickers: PLRX

TL;DR

PLRX filed an 8-K on June 5th for corporate updates - check for shareholder votes and bylaw changes.

AI Summary

Pliant Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting events as of June 5, 2025. The filing indicates amendments to its Articles of Incorporation or Bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. Specific details regarding these events, including any material changes or voting outcomes, are not elaborated upon in the provided text.

Why It Matters

This 8-K filing signals potential changes in Pliant Therapeutics' corporate structure or governance, which could impact its operational direction and shareholder rights.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative financial or operational news.

Key Players & Entities

  • PLIANT THERAPEUTICS, INC. (company) — Registrant
  • June 5, 2025 (date) — Earliest event reported
  • June 9, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of Incorporation
  • 001-39303 (commission_file_number) — SEC File Number
  • 47-4272481 (ein) — IRS Employer Identification No.

FAQ

What specific amendments were made to Pliant Therapeutics' Articles of Incorporation or Bylaws?

The provided text of the 8-K filing does not specify the details of the amendments made to the Articles of Incorporation or Bylaws.

What matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific proposals or resolutions are not detailed in the provided excerpt.

Are there any significant financial statements or exhibits included with this filing?

The filing states that Financial Statements and Exhibits are included, but the content or nature of these exhibits is not described in the provided text.

What is the exact date of the earliest event reported in this 8-K?

The earliest event reported in this 8-K filing is June 5, 2025.

What is the primary business of Pliant Therapeutics, Inc. according to the filing?

Pliant Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding PLIANT THERAPEUTICS, INC. (PLRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.